RHJA
LMAT icon

Rice Hall James & Associates’s LeMaitre Vascular LMAT Stock Holding History

Rice Hall James & Associates’s Portfolio LMAT Stock Details LMAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20.2M Buy
184,725
+2,449
+1% +$233K 1.12% 27
2025
Q4 		$14.8M Buy
182,276
+4,090
+2% +$352K 0.81% 41
2025
Q3 		$15.6M Sell
178,186
-35,684
-17% -$3.19M 0.85% 37
2025
Q2 		$17.8M Buy
213,870
+3,248
+2% +$271K 0.96% 30
2025
Q1 		$17.7M Sell
210,622
-24,454
-10% -$2.27M 1.04% 27
2024
Q4 		$21.7M Sell
235,076
-26,230
-10% -$2.52M 1.19% 23
2024
Q3 		$24.3M Buy
261,306
+35,383
+16% +$3.07M 1.31% 21
2024
Q2 		$18.6M Sell
225,923
-6,776
-3% -$498K 1.12% 23
2024
Q1 		$15.4M Buy
232,699
+462
+0.2% +$28.5K 0.88% 31
2023
Q4 		$13.2M Sell
232,237
-15,481
-6% -$811K 0.76% 41
2023
Q3 		$13.5M Sell
247,718
-4,700
-2% -$279K 0.86% 36
2023
Q2 		$17M Sell
252,418
-2,048
-0.8% -$125K 0.96% 30
2023
Q1 		$13.1M Sell
254,466
-836
-0.3% -$40.6K 0.74% 39
2022
Q4 		$11.7M Sell
255,302
-7,062
-3% -$331K 0.67% 41
2022
Q3 		$13.3M Sell
262,364
-4,390
-2% -$219K 0.77% 42
2022
Q2 		$12.2M Buy
266,754
+4,881
+2% +$218K 0.59% 50
2022
Q1 		$12.2M Buy
261,873
+6,781
+3% +$303K 0.48% 59
2021
Q4 		$12.8M Buy
255,092
+2,823
+1% +$146K 0.45% 54
2021
Q3 		$13.4M Buy
252,269
+4,393
+2% +$247K 0.49% 61
2021
Q2 		$15.1M Buy
247,876
+18,370
+8% +$976K 0.54% 58
2021
Q1 		$11.2M Buy
229,506
+21,455
+10% +$1.01M 0.36% 65
2020
Q4 		$8.43M Buy
208,051
+168,188
+422% +$6.01M 0.3% 72
2020
Q3 		$1.3M Buy
39,863
+2,627
+7% +$78.9K 0.05% 215
2020
Q2 		$983K Sell
37,236
-26,457
-42% -$692K 0.04% 212
2020
Q1 		$1.59M Sell
63,693
-941
-1% -$29.1K 0.09% 161
2019
Q4 		$2.32M Sell
64,634
-861
-1% -$29.7K 0.08% 152
2019
Q3 		$2.24M Sell
65,495
-3,653
-5% -$117K 0.08% 155
2019
Q2 		$1.94M Sell
69,148
-4,825
-7% -$134K 0.06% 182
2019
Q1 		$2.29M Sell
73,973
-3,332
-4% -$88.9K 0.07% 166
2018
Q4 		$1.83M Buy
77,305
+30,174
+64% +$824K 0.07% 183
2018
Q3 		$1.83M Sell
47,131
-11,360
-19% -$409K 0.07% 196
2018
Q2 		$1.96M Sell
58,491
-100
-0.2% -$3.56K 0.07% 206
2018
Q1 		$2.12M Sell
58,591
-13,071
-18% -$453K 0.08% 173
2017
Q4 		$2.28M Sell
71,662
-3,830
-5% -$131K 0.09% 183
2017
Q3 		$2.83M Sell
75,492
-244
-0.3% -$8.3K 0.13% 138
2017
Q2 		$2.36M Sell
75,736
-37,667
-33% -$1.09M 0.1% 164
2017
Q1 		$2.79M Sell
113,403
-42,861
-27% -$1.01M 0.14% 127
2016
Q4 		$3.96M Sell
156,264
-500
-0.3% -$11.1K 0.2% 102
2016
Q3 		$3.11M Sell
156,764
-1,400
-0.9% -$24.5K 0.16% 114
2016
Q2 		$2.26M Sell
158,164
-51,477
-25% -$787K 0.13% 150
2016
Q1 		$3.25M Buy
209,641
+1,000
+0.5% +$14.3K 0.19% 106
2015
Q4 		$3.6M Sell
208,641
-2,500
-1% -$36.2K 0.21% 106
2015
Q3 		$2.57M Buy
211,141
+4,000
+2% +$51.3K 0.17% 138
2015
Q2 		$2.5M Sell
207,141
-1,875
-0.9% -$18.5K 0.14% 156
2015
Q1 		$1.75M Buy
209,016
+97,348
+87% +$764K 0.1% 208
2014
Q4 		$854K Buy
+111,668
New +$799K 0.05% 248

Other funds holding LMAT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CCM
Copeland Capital Management Conshohocken, Pennsylvania $4.5B AUM 18.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
GCM
Geneva Capital Management Milwaukee, Wisconsin $4.71B AUM 6.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Rice Hall James & Associates's LMAT Position: Q1 2026 in Review

Rice Hall James & Associates increased its LeMaitre Vascular (LMAT) stake by 1.3% in Q1 2026, buying an estimated $233K and bringing the position to 184,725 shares worth $20.2M. The position accounts for 1.12% of the portfolio, ranked #27.

Rice Hall James & Associates first reported a position in LMAT in Q4 2014 and has held it in 46 quarters since. The position peaked at $24.3M in Q3 2024. 339 funds tracked by Wall St. Rank hold LMAT as of Q1 2026.

  • Rice Hall James & Associates held 184,725 shares of LeMaitre Vascular worth $20.2M as of Q1 2026.
  • Rice Hall James & Associates bought 2,449 LeMaitre Vascular shares in Q1 2026, an estimated $233K.
  • LeMaitre Vascular made up 1.12% of Rice Hall James & Associates's portfolio in Q1 2026, its #27 holding.
  • Rice Hall James & Associates first reported a position in LeMaitre Vascular in Q4 2014 and has held it in 46 quarters since.
  • Rice Hall James & Associates's LeMaitre Vascular position peaked at $24.3M in Q3 2024.
  • 339 funds tracked by Wall St. Rank held LeMaitre Vascular as of Q1 2026.

Based on Rice Hall James & Associates's 13F filing for Q1 2026, filed 15 May 2026.